Skip to main content
. 2021 Sep 25;2021:6256369. doi: 10.1155/2021/6256369

Figure 1.

Figure 1

The levels of BAIAP2-AS1 in HCC patients and its clinical significance. (a) The levels of BAIAP2-AS1 in HCC and normal liver specimens based on TCGA datasets (tumor: n = 369, normal: n = 160). (b) Pan-cancer expression of BAIAP2-AS1 using TCGA datasets. (c) RT-qPCR assay was applied to analyze BAIAP2-AS1 expression in fresh HCC specimens and matched control tissues. (d) The expression of BAIAP2-AS1 in LO2 cells and HCC cell lines Huh7, HCCLM3, HepG2, and PLC5. (e) The association between the dysregulated BAIAP2-AS1 and clinical survivals by analyzing TCGA datasets (n = 364). ∗p < 0.05,  ∗∗p < 0.01, and∗∗∗p < 0.001.